AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI) setting, at the American Society of Nephrology (ASN) meeting Kidney Week in Atlanta, GA, USA. The research was conducted by Prof. Dr. Can Ince and his team at the Department of Translational Physiology, Academic Medical Center, University of Amsterdam, the Netherlands.